Increased integrin β1 contributes to resistance to anti-HER2 (trastuzumab or lapatinib) and anti-PI3K (pertuzumab) via the activation of FAK/Src signaling in HER2-positive breast cancer (199, 200). Here, ERBB2 is linked to breast carcinoma.